Anders Lilja is SVP Technical Development at HOOKIPA. He is responsible for developing HOOKIPA’s promising product candidates from research through GMP manufacturing. While at HOOKIPA, he led the development of our cytomegalovirus vaccine candidate HB-101 through the phase 1 clinical trial. Prior to joining HOOKIPA, he was a Research Investigator and Associate Research Project Leader at Novartis Vaccines. He holds an MSc in chemical engineering from Chalmers University of Technology, Sweden, a PhD in Biochemistry from University of Maryland, and did postdoctoral training in molecular virology at Princeton University. He has co-authored several publications characterizing key cytomegalovirus vaccine antigens.